¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"total pulmonary resistance"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • extralobar pulmonary sequestration
    ¿±¿ÜÇãÆÄºÐ¸®Áõ, ¿±¿ÜÆóºÐ¸®Áõ
  • hypertrophic pulmonary osteoarthropathy
    ºñ´ë¼ºÆó»À°üÀýº´(Áõ)
  • high altitude pulmonary edema
    °íÁö´ëÆóºÎÁ¾
  • hantavirus pulmonary syndrome
    ÇÑŸ¹ÙÀÌ·¯½ºÆóÁõÈıº
  • idiopathic pulmonary fibrosis
    Ư¹ßÆó¼¶À¯Áõ
  • intralobar pulmonary sequestration
    ¿±³»ÇãÆÄºÐ¸®Áõ, ¿±³»ÆóºÐ¸®Áõ
  • neurogenic pulmonary edema
    ½Å°æ¼ºÆóºÎÁ¾
  • obstructive pulmonary disease
    Æó¼âÆóº´
  • plexogenic pulmonary arteriopathy
    ¾ó±âÇü¼ºÆóµ¿¸Æº´(Áõ)
  • pulmonary
    Æó-, ÇãÆÄ-
  • pulmonary actinomycosis
    Æó¹æ¼±±ÕÁõ, ÇãÆÄ¹ÙÄû»ì±ÕÁõ
  • pulmonary adenomatosis
    Æó»ùÁ¾Áõ, Æó¼±Á¾Áõ
  • pulmonary alveolar microlithiasis
    ÆóÆ÷¹Ì¼¼°á¼®Áõ
  • pulmonary alveolar proteinosis
    ÇãÆÄ²Ê¸®´Ü¹éÁõ, ÆóÆ÷´Ü¹éÁõ
  • pulmonary alveolus
    ÇãÆÄ²Ê¸®, ÆóÆ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • donor resistance
    ÁÖ´ÂÀÌÀúÇ×¼º
  • drug resistance
    ¾à¹°³»¼º
  • drug resistance factor
    ¾àÁ¦ÀúÇ×ÀÎÀÚ
  • resistance donor
    ÀúÇ×¼ºÁ¦°øÃ¼, ÀúÇ×¼ºÁÖ°Ô
  • effective membrane resistance
    À¯È¿¸·ÀúÇ×
  • electric skin resistance
    ÇǺÎÀü±âÀúÇ×
  • progressive resistance exercise
    Á¡ÁõÀúÇ׿
  • flow resistance
    È帧ÀúÇ×, À¯·®ÀúÇ×
  • frictional resistance
    ¸¶ÂûÀúÇ×
  • resistance factor
    ³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
  • resistance furnace
    ÀúÇ×·Î
  • genetic resistance
    À¯ÀüÀúÇ×
  • heterogeneous resistance
    ºñ±ÕÀÏÀúÇ×
  • insulation resistance
    Àý¿¬ÀúÇ×
  • insulin resistance
    Àν¶¸°ÀúÇ×
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • hypoxic pulmonary vasoconstriction
    Àú»ê¼Ò¼º ÆóÇ÷°ü¼öÃà.
  • idiopathic pulmonary fibrosis
    Ư¹ß¼º Æó¼¶À¯È­Áõ(¡­øËàéë«ûùñø)
  • idiopathic pulmonary hemosiderosis
    Ư¹ß¼º ÆóÇ÷öÁõ(¡­øËúìôÑñø).
  • idiopathic pulmonary hemosiderosis
    Ư¹ß¼º ÆóÇ÷öÁõ
  • plexogenic pulmonary arteriopathy
    ÃÑÇü¼º Æóµ¿¸Æº´Áõ(õ¿û¡àõ øËÔÑØæÜ»ñø)
  • posterior pulmonary lymph nodes
    µÚÆó¸²ÇÁÀý, ÈÄÆó(ý­øË)¸²ÇÁÀý.
  • primary pulmonary hypertension
    ¿ø¹ß(¼º) Æó°íÇ÷¾ÐÁõ(¡­øËÍÔúìäâñø).
  • primary pulmonary hypertension
    ¿ø¹ß(¼º) Æó°íÇ÷¾ÐÁõ(ê«Û¡(àõ) øËÍÔúìäâñø)
  • primary pulmonary lobule
    ÀÏÂ÷ÇãÆÄ¼Ò¿±
  • proteinosis, pulmonary alveolar
    ´Ü¹é(Áú)Áõ(Ó±ÛÜ(òõ)ñø), ÆóÆ÷¼º(øËøààõ)
  • pulmonary
    ÆóÀÇ
  • pulmonary
    ÆóÀÇ(øË¡­)
  • pulmonary P
    Æó¼ºP ½ÉÀüµµ¿ë¾î .
  • pulmonary T
    Æó¼ºT ½ÉÀüµµ¿ë¾î .
  • pulmonary abscess
    Æó³ó¾ç(øËÒÛåË).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • index of resistance
    ÀúÇ×Áö¼ö(î½ù÷ò¦â¦).
  • insulation resistance
    Àý¿¬ÀúÇ×(ï¾æÞî½ù÷).
  • insulin resistance
    Àν¶¸°ÀúÇ×¼º.
  • internal resistance =IR
    ³»ºÎÀúÇ×(Үݻî½ù÷).
  • intrinsic resistance
    º»Å¼º ³»¼º
  • loss of resistance method
    ÀúÇ׼ҽǹý
  • multidrug resistance gene family
  • multiple drug resistance
    ´ÙÁ¦³»¼º
  • multiple drug resistance gene
    º¹ÇÕ¾àÁ¦³»¼ºÀ¯ÀüÀÚ
  • natural resistance
    ÀÚ¿¬ÀúÇ×·Â(¼º)(í»æÔî½ù÷æ³àõ), ÀÚ¿¬³»¼º(~Ò±àõ).
  • one step high level resistance
    ÀÏ´Ü°è °íµµ ³»¼ºÈ¹µæ, ÀÏȸ °í³»¼ºÈ¹µæ
  • osmotic resistance
    »ïÅõ¾ÐÀúÇ×(¡­î½ù÷).
  • passive resistance
    Çǵ¿ÀúÇ×(ù¬ÔÑî½ù÷).
  • peripheral resistance
    ¸»ÃÊÀúÇ×(¡­î½ù÷).
  • peripheral resistance unit
    ¸»ÃÊÀúÇ×´ÜÀ§(¡­Ó¤êÈ).
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • restrictive pulmonary disease
    ±¸¼Ó¼ºÆóÁúȯ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
RVR reduced vascular response; renal vascular resistance; repetitive ventricular response; resistance to...
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
PAH para-aminohippurate; phenylalanine hydrolase; polycyclic aromatic hydrocarbon; predicted adult heigh...
PC avoirdupois weight [Lat. pondus civile]; packed cells; paper chromatography; paracortex; parent cell...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
TAPVR Total anomalous pulmonary venous return
total-C Total cholesterol
TGR 6-thioguanine resistance
APCR Activated Protein C Resistance
ars Arsenical resistance
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • total growth
    ÃÑ Áõ½Ä·®
  • total hematuria
    Àü Ç÷´¢Áõ
  • total hyperplasia
    Àüü °ú´Ù Çü¼º
  • total hysterectomy
    Àü Àڱà ÀýÁ¦¼ú
  • total inversion
    Àüü ÀÚ¸®¹Ù²Þ
  • total irradiation
    Àü½Å Á¶»ç
  • total laryngectomy
    ÈĵΠÀü ÀûÃâ¼ú
  • total lymphoid irradiation
    Àü ¸²ÇÁ Á¶»ç
  • total nephrectomy
    ½Å Àü ÀýÁ¦, ½Å Àü ÀýÁ¦¼ú
  • total nerve block
    ¿ÏÀü Àü´Þ ¸¶Ãë
  • total nodal irradiation
    Àü ¸²ÇÁÀý Á¶»ç
  • total organ duplication
    Àüü ±â°ü Áߺ¹
  • total organism
    Àü½Å ±â°ü
  • total oxidation process
    ¿ÏÀü »êÈ­¹ý
  • total parenteral alimentation
    Àü ºñ °æ±¸Àû ¿µ¾ç ¼öÁÖ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
insulin resistance Many people with noninsulin-dependent diabetes produce enough insulin, but their bodies do not respond to the action of insulin. This may happen because the person is overweight and has too many fat cells, which do not respond well to insulin. Also, as people age, their body cells lose some of the ability to respond to insulin. Insulin resistance is also linked to high blood pressure and high levels of fat in the blood. Another kind of insulin resistance may happen in some people who take insulin injections. They may have to take very high doses of insulin every day (200 units or more) to bring their blood glucose (sugar) down to the normal range.
(09 Oct 1997)
tetracycline resistance Nonsusceptibility of a microbe (usually a bacterium) to the action of tetracycline, which binds to the 30s ribosomal subunit and prevents the normal binding of aminoacyl-trna.
(12 Dec 1998)
thyroid hormone resistance syndrome <syndrome> An inherited syndrome of peripheral resistance to thyroid hormones, transmitted as an autosomal recessive trait, characterised by increased serum concentrations of thyroxine and triiodothyronine, increased thyroid hormone binding ratio, and normal to slightly increased thyroid-stimulating hormone and its response to thyrotropin-releasing hormone. The affected persons are euthyroid to slightly hypothyroid. The absence of hypermetabolism and the presence of possible hypothyroidism indicate the existence of partial resistance to the peripheral action of thyroid hormone.
(12 Dec 1998)
thyrotropin resistance An autosomal recessive disorder in which the thyrocytes are unresponsive to thyrotropin.
Compare: pseudohypoparathyroidism.
(05 Mar 2000)
trimethoprim resistance Nonsusceptibility of a bacterium to the action of trimethoprim.
(12 Dec 1998)
expiratory resistance Resistance to flow of gas out of the lungs or the total resistance to flow of gas during the expiratory phase of the respiratory cycle.
(05 Mar 2000)
kanamycin resistance Nonsusceptibility of bacteria to the antibiotic kanamycin, which can bind to their 70s ribosomes and cause misreading of messenger RNA.
(12 Dec 1998)
radical mastectomy, total Breast cancer treatment involving removal of the breast, the pectoral (chest) muscles, lymph nodes (the glands ) in the armpit and associated skin and subcutaneous tissue.
(12 Dec 1998)
parenteral nutrition, home total The at-home administering of nutrients for assimilation and utilization by a patient whose sole source of nutrients is via solutions administered intravenously, subcutaneously or by some other non-alimentary route.
(12 Dec 1998)
parenteral nutrition, total The delivery of nutrients for assimilation and utilization by a patient whose sole source of nutrients is via solutions administered intravenously, subcutaneously, or by some other non-alimentary route. The basic components of tpn solutions are protein hydrolysates or free amino acid mixtures, monosaccharides, and electrolytes. Components are selected for their ability to reverse catabolism, promote anabolism, and build structural proteins.
(12 Dec 1998)
reversal of organs, total This condition (medically called situs inversus totalis) involves complete transposition (right to left reversal) of the thoracic and abdominal organs. The heart is not in its usual position in the left chest but is on the right. Specifically related to the heart, this is referred to as dextrocardia (literally, right-hearted). And the stomach, which is normally in the left upper abdomen, is on the right. In patients with situs inversus totalis, all of the chest and abdominal organs are reversed and appear in mirror image when examined or visualised by tests such as X-ray filming. Situs inversus totalis has been estimated to occur once in about 6-8,000 births. Situs inversus occurs in a rare abnormal condition that is present at birth (congenital) called kartagener's syndrome.
(12 Dec 1998)
communication methods, total Utilization of all available receptive and expressive modes for the purpose of achieving communication with the hearing impaired, such as gestures, postures, facial expression, types of voice, formal speech and non-speech systems, and simultaneous communication.
(12 Dec 1998)
congenital total lipodystrophy Lipodystrophy characterised by almost complete lack of subcutaneous fat, accelerated rate of growth and skeletal development during the first 3 to 4 years of life, muscular hypertrophy, cardiac enlargement, hepatosplenomegaly, hypertrichosis, renal enlargement, hypertriglyceridemia, and hypermetabolism; both autosomal dominant and X-linked varieties exist.
(05 Mar 2000)
hysterectomy, total Complete surgical removal of the uterus and cervix. Also called a complete hysterectomy.
(12 Dec 1998)
near-total thyroidectomy Removal of nearly all of each thyroid lobe leaving unresected only a small portion of gland adjacent to the entrance of the recurrent laryngeal nerve into the larynx.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á